Posted by Michael Wonder on 18 Jun 2021
Outcomes of the May 2021 PBAC intracycle meeting
18 June 2021 - The outcomes from the May 2021 PBAC meeting are now available.
The PBAC (once again) deferred the listing of:
- Elexacaftor with tezacaftor and ivacaftor - new combination product
- Encorafenib - new indication
- Onasemnogene abeparvovec - new gene therapy
